Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Numinus Wellness: The mental health business is estimated to grow to $530 billion by 2030

Numinus Wellness is in the business of psychedelic medicine but, more importantly, the mental health business. The mental health business is a sector that will be worth an estimated $530 billion dollars by the year 2030. Numinus has already seen more than a 618% ...
Brieanna McCutcheon | January 30, 2023 |

HAVN Life Sciences: Using psychedelics, specifically mushrooms, to improve mental health

Mental health, as we know, controls a large part of how we interact with the world around us. Our next guest knows this and is working to improve the mental health of those struggling by using psychedelics, specifically mushrooms. Psychedelics are not federally l...
Brieanna McCutcheon | November 4, 2022 |

Novamind’s Trial Site for Merck Another Example Of Its Leadership in Mental Health

Novamind’s clinics and clinical research capabilities are already well established to bring alternative mental health therapies, including psychedelic medicine, to market. One of the world’s largest pharmaceutical companies has selected ...
Featured Submission | March 24, 2021 |

Bob Moriarty's Thoughts on the Coronavirus

If there was ever a time for real leaders to step forward and lead, the last four months would have been the time to do so. If there was an issue that demanded cooperation from all the nations of the world, we have seen it. Instead we have been fed a steady diet of disinf...
Streetwise Reports | April 20, 2020 |

Economic stimulus can’t save US from deflation and recession

One of the worst weeks on Wall Street mercifully ended on Friday. S&P 500 DJIA Nasdaq After multiple sessions of panic selling, the markets caught an up-draft after US President Trump declared a national emergency over the coronavirus, thus freeing u...
Richard (Rick) Mills | March 16, 2020 |

TESLA - does a short squeeze like once at Volkswagen threaten?

In the language of traders, the covering of short position in a rapidly rising market with a scarce supply is called short squeeze. So-called short sellers have previously borrowed shares from banks or other investors and then sold them because they wanted to bet on falling pr...
Mario Hose | January 23, 2020 |

Buzz on the Bullboards: Aphria and Bombardier On Top

Long live the kings? That was the question last week, a roller coaster for markets as indexes hit record highs while company earnings saw major names soar and fall in equal measure. Tapping into the largest public market investor hub in Canada, the Stockhouse Bullboards, i...
Omri Wallach | January 22, 2020 |

How on Earth Can Gold Decline During the U.S. – Iran Crisis?

So, did U.S. and Iran just become best friends? Gold’s huge reversal and a decline of about $50 in 24 hours might certainly suggest so to those, who choose to follow the news instead of estimating market’s moves using more reliable tools. ...
Przemyslaw Radomski, CFA | January 9, 2020 |

Axsome Therapeutics Shares Open 82% Higher on Phase 3 MDD Trial Outcome

Axsome Therapeutics shares reached a new 52-week high price today after the company reported that its AXS-05 drug achieved primary endpoint in the GEMINI Phase 3 trial in Major Depressive Disorder. The firm indicated that the positive results support a New Drug Application fil...
Streetwise Reports | December 17, 2019 |

Buzz on the Bullboards: Big Last-Minute Moves

Though some may have expected the markets to be relaxed heading into the holidays, many investors and brokers know that this is their time to shine. With every twist and turn the global economy has been throwing our way, staying active is definitely the right move. And as ...
Omri Wallach | December 11, 2019 |
1 2